Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Taxane‐related peripheral neuropathy (TrPN) is a dose‐limiting toxicity with important interindividual variability. Genetic polymorphisms in absorption, distribution, metabolism, and excretion (ADME) genes may account for variability in drug efficacy and/or toxicity. By the use of Affymetrix drug‐metabolizing enzyme and transporter microarray platform, in a retrospective case‐control study, the correlation between ADME polymorphic variants and grades ≥ 2−3‐TrPN was investigated. In a breast cancer (BC) training set, five single‐nucleotide polymorphisms in NR1I3 and UDP‐glucuronosyltransferase (UGT)2B7 genes were correlated to grades ≥ 2−3‐TrPN protection. By receiver operating characteristic curves, the grades ≥ 2−3‐TrPN‐related candidate biomarkers in an independent series of 54 patients with BC (17 cases and 37 controls) were validated. NR1I3 was correlated to paclitaxel‐TrPN and UGT2B7 to docetaxel‐TrPN. Moreover, a genetic signature of prognostic relevance for BC outcome was found. Our findings might have potential relevance for personalized management of patients with BC for prevention of treatment failure in ultrametabolizer genetic variants.

[1]  Jeffrey Bell,et al.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[2]  F. Balloux,et al.  Discriminant analysis of principal components: a new method for the analysis of genetically structured populations , 2010, BMC Genetics.

[3]  M. Smid,et al.  Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics , 2015, The Pharmacogenomics Journal.

[4]  Ronald W. Davis,et al.  Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.

[5]  Yusuke Nakamura,et al.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.

[6]  L. Carey,et al.  CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Douglas G. Altman,et al.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration , 2012, PLoS medicine.

[8]  Mario Cannataro,et al.  DMET-Analyzer: automatic analysis of Affymetrix DMET Data , 2012, BMC Bioinformatics.

[9]  Mario Cannataro,et al.  Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis , 2015, Cancer Chemotherapy and Pharmacology.

[10]  Mario Cannataro,et al.  Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study , 2011, Cancer biology & therapy.

[11]  Bradley L Urquhart,et al.  Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.

[12]  W. Engel-Riedel,et al.  A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer , 2018, Journal of Immunotherapy for Cancer.

[13]  E. Tan,et al.  Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients , 2013, European Journal of Clinical Pharmacology.

[14]  P. Mackenzie,et al.  Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region , 2015, Molecular Pharmacology.

[15]  U. Langsenlehner,et al.  Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer , 2011, Breast Cancer Research.

[16]  A. Starlard-Davenport,et al.  Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues , 2008, Steroids.

[17]  Giuseppe Agapito,et al.  Genetic variants associated with Fabry disease progression despite enzyme replacement therapy , 2017, Oncotarget.

[18]  Giuseppe Agapito,et al.  Genetic variants associated with gastrointestinal symptoms in Fabry disease , 2016, Oncotarget.

[19]  Taosheng Chen,et al.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. , 2017, Current drug metabolism.

[20]  Mario Cannataro,et al.  DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine , 2016, Oncotarget.

[21]  K. Haruma,et al.  Single nucleotide polymorphism markers for low‐dose aspirin‐associated peptic ulcer and ulcer bleeding , 2014, Journal of gastroenterology and hepatology.

[22]  Mario Cannataro,et al.  A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling , 2011, British journal of haematology.

[23]  K. Kuroi,et al.  Neurotoxicity of taxanes: Symptoms and quality of life assessment , 2004, Breast cancer.

[24]  W. Vach,et al.  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer , 2011, European Journal of Clinical Pharmacology.

[25]  G. Toffoli,et al.  Nuclear receptors and drug metabolism for the personalization of cancer therapy , 2016, Expert opinion on drug metabolism & toxicology.

[26]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[27]  M. Koltzenburg,et al.  Peripheral nerve damage associated with administration of taxanes in patients with cancer. , 2008, Critical reviews in oncology/hematology.

[28]  P. Mackenzie,et al.  Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7. , 2003, Biochemical pharmacology.

[29]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[30]  C. Caldas,et al.  Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel , 2014, Clinical Cancer Research.

[31]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[32]  I. Pogribny,et al.  The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance. , 2010, Experimental oncology.

[33]  M. Negishi,et al.  Sulfotransferase genes: Regulation by nuclear receptors in response to xeno/endo-biotics , 2013, Drug metabolism reviews.

[34]  R. Milne,et al.  Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.

[35]  E. Wiemer,et al.  CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity , 2013, Clinical Cancer Research.

[36]  U. Argikar,et al.  UDP-Glucuronosyltransferases , 2019, Handbook of Drug Metabolism.

[37]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[38]  S. Aliño,et al.  SNPs and taxane toxicity in breast cancer patients. , 2014, Pharmacogenomics.

[39]  A. Tsalenko,et al.  SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance , 2010, The Pharmacogenomics Journal.

[40]  David J. Hand,et al.  A Simple Generalisation of the Area Under the ROC Curve for Multiple Class Classification Problems , 2001, Machine Learning.

[41]  A. H. Tolson,et al.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. , 2010, Advanced drug delivery reviews.